Holen Sie sich die Stockscreener-App
119.59
0.49%
0.6417
Schlusskurs vom Vortag:
$118.95
Offen:
$118.95
24-Stunden-Volumen:
1.37M
Relative Volume:
0.65
Marktkapitalisierung:
$15.87B
Einnahmen:
$1.08B
Nettoeinkommen (Verlust:
$-433.19M
KGV:
-35.17
EPS:
-3.4004
Netto-Cashflow:
$-225.09M
1W Leistung:
+21.74%
1M Leistung:
+34.44%
6M Leistung:
+10.90%
1J Leistung:
+214.56%
1-Tages-Spanne:
$115.30
$120.35
1-Wochen-Bereich:
$100.48
$121.01
52-Wochen-Spanne:
$37.73
$121.01
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
119.67 | 15.77B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
448.79 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
173.06 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.96 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
339.52 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.54 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Bestätigt | Canaccord Genuity | Buy |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-09-25 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
BTIG raises Guardant Health stock price target on FDA approval By Investing.com - Investing.com Canada
Guardant Health, Inc. (GH) Stock Analysis: 48.3% Revenue Growth Fuels Investor Optimism - DirectorsTalk Interviews
Guardant gets FDA nod for next-gen cancer mutation blood test - Mugglehead Investment Magazine
Guardant wins FDA nod for Guardant360 Liquid CDx cancer test - MSN
A Look At Guardant Health’s Valuation After Its Recent Share Price Surge - Yahoo Finance
Guardant Health (GH) Is Up 25.3% After FDA Clears First Genomic‑Epigenomic Liquid Biopsy Panel – Has The Bull Case Changed? - Yahoo Finance
Guardant Health Stock 5-Day Winning Spree: Stock Climbs 25% - Trefis
Guardant Health Stock On Fire: Up 25% With 5-Day Winning Streak - Trefis
Insider Sell: John Saia Sells 20,000 Shares of Guardant Health I - GuruFocus
Guardant Health director Ian T. Clark disposes of $735k in shares - Investing.com UK
Guardant Health chief legal officer sells $2.13m in stock - Investing.com UK
Guardant Health director Ian T. Clark disposes of $735k in shares By Investing.com - Investing.com South Africa
Guardant Health chief legal officer sells $2.13m in stock By Investing.com - Investing.com Australia
Guardant Health insider cashless exercise reported (NASDAQ: GH) - Stock Titan
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health Insider Sold Shares Worth $23,076,690, According to a Recent SEC Filing - Moomoo
Guardant Health Insider Sold Shares Worth $2,130,229, According to a Recent SEC Filing - Moomoo
Guardant Health (GH) Chief Legal Officer sells 20,000 shares in open-market trades - Stock Titan
Guardant Health (GH) co-CEO’s family trust sells 210K shares of stock - Stock Titan
Family trust of Guardant Health (NASDAQ: GH) director sells 6,876 shares in open market - Stock Titan
Guardant Health (NASDAQ: GH) director sells 1,250 shares after exercising options - Stock Titan
Guardant Health stock gains on early FDA approval for G360 test By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at 120.74 USD By Investing.com - Investing.com Nigeria
Research Alert: CFRA Maintains Buy Rating On Shares Of Guardant Health - Moomoo
Guardant Health stock hits 52-week high at 120.74 USD - Investing.com
Guardant Health stock gains on early FDA approval for G360 test - Investing.com Australia
Guardant wins FDA approval for updated liquid biopsy - MedTech Dive
NORTH SQUARE DYNAMIC SMALL CAP FUND's Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health leaps on a major win in cancer detection; will shares break out? - MSN
Guardant Health (GH) Shares Rise Following FDA Approval of Guard - GuruFocus
Why Guardant Health (GH) Is Up 16.8% After Hiking 2026 Revenue Guidance on Shield Momentum - simplywall.st
Guardant Health (GH) Gains FDA Approval for New Liquid Biopsy Te - GuruFocus
Guardant Health secures FDA approval for expanded liquid biopsy test - MSN
Guardant Health (GH) Form 144 lists brokered proposed sales and restricted stock lapses - Stock Titan
Guardant Health (NASDAQ: GH) affiliate sale notice; 1,300 shares sold previously - Stock Titan
Guardant Health Stock Climbs As Q1 Beat Fuels Bullish Targets - StocksToTrade
Guardant Health receives FDA approval for expanded liquid biopsy test By Investing.com - Investing.com Australia
Guardant Health Stock Climbs As Growth Story Accelerates - timothysykes.com
Guardant Health Stock Rallies After Shield-Fueled Earnings Beat - StocksToTrade
Why is Guardant Health stock surging today? By Investing.com - Investing.com Australia
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy TestGuardant Health (NASDAQ:GH) - Benzinga
FDA approval advances personalized cancer diagnostics - BioWorld News
Guardant Health Stock Jumps 10% to $108 on Momentum From Record Q1 Revenue Beat and Raised Guidance - International Business Times Australia
Guardant Health Stock Builds Momentum After Q1 Beat And Analyst Upgrades - timothysykes.com
Guardant Health Receives FDA Approval for New Cancer Test - Intellectia AI
Quinn Emanuel Gets $3 Million Sanction in Drug Advertising Case - Bloomberg Law News
Guardant wins FDA nod for Guardant360 Liquid CDx (GH:NASDAQ) - Seeking Alpha
Guardant Health Receives FDA Approval for New Liquid Biopsy - Intellectia AI
Guardant Health receives FDA approval for expanded liquid biopsy test - Investing.com
Guardant Health Says US FDA Approved Liquid Biopsy Test - Moomoo
Fda approves new Guardant360 liquid cdx, the largest FDA-approved liquid biopsy panel with a 100x expanded footprint - marketscreener.com
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):